Title:
併用のためのＢＣＭＡ及びＣＤ３に対する抗増殖性化合物及び二重特異性抗体
Document Type and Number:
Japanese Patent JP7293256
Kind Code:
B2
Abstract:
Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof in combination with a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and human CD3ε (CD3) for use in a method of treating multiple myeloma, wherein the method comprises administering an additional active agent selected from the group consisting of daratumumab, bortezomib, and dexamethasone.
Inventors:
Daniel W. Pierce
Lily L. Wong
Lily L. Wong
Application Number:
JP2020565359A
Publication Date:
June 19, 2023
Filing Date:
May 22, 2019
Export Citation:
Assignee:
Celgene Corporation
International Classes:
A61K39/395; A61K31/496; A61P35/00; A61P35/02; A61P43/00; C07D401/04
Foreign References:
| WO2018083204A1 | ||||
| WO2017021450A1 | ||||
| WO2019014100A1 | ||||
| WO2016166629A1 |
Attorney, Agent or Firm:
Toru Ishikawa
Previous Patent: Physical Vapor Deposition Biosensor Components
Next Patent: INTAKE DEVICE OF INTERNAL COMBUSTION ENGINE
Next Patent: INTAKE DEVICE OF INTERNAL COMBUSTION ENGINE